Global Methylene Blue Enteric-coated Sustained-release Tablets Market Strategic Research Report

Scope of the Report

The global Methylene Blue Enteric-coated Sustained-release Tablets market size is predicted to grow from US$ 15.46 million in 2025 to US$ 39.12 million in 2032; it is expected to grow at a CAGR of 5.8% from 2026 to 2032.

Methylene Blue Enteric-coated Sustained-release Tablets are solid enteric-coated and sustained-release preparations with methylene blue as the main active ingredient. Adopting combined technologies of enteric coating and sustained-release formulation, the drug avoids decomposition and destruction in the stomach, enabling the active ingredients to be released slowly and continuously in a targeted manner in the intestinal tract. With a unique targeted staining effect, it is mainly applied in colonoscopy examinations to improve the identification of intestinal mucosal lesions and assist the early screening and diagnosis of tiny colorectal lesions. The sustained-release dosage form steadily controls the drug release rate, reduces local irritation, and improves medication safety and tolerability, providing important auxiliary medication support for the accurate clinical diagnosis and treatment of intestinal diseases.In 2025, global production of Methylene Blue Enteric-coated Sustained-release Tablets reached approximately 2.1 million bottles.

Methylene Blue Enteric-coated Sustained-release Tablets, as the world’s first oral colon-targeted staining diagnostic preparation, has become a key product in the field of early colorectal cancer screening by virtue of its unique enteric-coated and sustained-release technology and prominent clinical value. Originally developed by Cosmo Pharma, it was first launched in the European Union and later introduced and approved in China by C&P Pharmaceutical, filling the domestic gap in oral diagnostic drugs for intestinal staining. With the rising global incidence of colorectal cancer and growing awareness of early screening, the demand for colonoscopy continues to expand, creating broad market prospects for this product. Compared with traditional intraoperative staining methods, this drug features convenient oral administration and can be taken simultaneously during intestinal preparation, greatly improving examination efficiency and patient compliance. Its clinical advantages lie in precisely staining the intestinal mucosa, elevating the detection rate of minute and flat lesions, facilitating early clinical intervention and optimizing patient prognosis. At present, the market competition pattern remains favorable. Supported by patented technologies and first-mover advantages, the product has formed high market barriers. With the continuous promotion of clinical indications and the expected inclusion in medical insurance, its market penetration is projected to increase steadily in the future, making it a vital growth driver in the field of intestinal disease diagnosis.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Methylene Blue Enteric-coated Sustained-release Tablets market?

What factors are driving Methylene Blue Enteric-coated Sustained-release Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Methylene Blue Enteric-coated Sustained-release Tablets market opportunities vary by end market size?

How does Methylene Blue Enteric-coated Sustained-release Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Methylene Blue Enteric-coated Sustained-release Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 25 mg
• 50 mg

Segment by Dosage Form

• Enteric-coated Sustained-release Tablets
• Colon-targeted Sustained-release Solid Preparation

Segment by Sales Channel

• Hospital
• Retail
• Online

Segment by Application

• Colorectal Lesion Screening
• Intestinal Mucosa Staining Imaging
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Methylene Blue Enteric-coated Sustained-release Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Colorectal Lesion Screening, Intestinal Mucosa Staining Imaging, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact